The global diabetes treatment market size was valued at about USD 30 bn in 2022 and is anticipated to reach USD 55 bn by 2031, expanding at a CAGR of 5% during the forecast period, 2022–2031. Introduction of new analytical technologies and developments of diabetes treatments are expected to fuel the market.
The body breaks down the food that is consumed into sugar or glucose, which is released into the bloodstream. When the blood sugar rises, it signals the pancreas to release insulin, which allows the sugar in the bloodstream to enter the body’s cells to use as energy.
Diabetes is a health condition in which the body is unable to utilize the glucose produced in the body. When enough insulin is not produced by the body, the cells in the body stop responding to it, thus a lot of the blood sugar stays in the bloodstream. This, overtime, causes health issues, such as heart disease, vision loss, and kidney disease.
According to The Centers for Disease Control and Prevention (CDC), the three main types of diabetes are type 1, type 2, and gestational diabetes. Type 1 diabetes is an autoimmune reaction, which prevents the body from producing insulin. It develops quickly, and is usually diagnosed among children, teenagers, and young adults.
In type 2 diabetes, the body does not use the insulin. This form of diabetes occurs over time and is diagnosed among people of varying ages. Its symptoms include weight loss, frequent urination, increased thirst and hunger, fatigue, high susceptibility to infections, slow healing of wounds, and blurry vision.
Gestational diabetes occurs among pregnant women, and can be temporary. If left untreated, it can cause health problem in the baby. This form of diabetes often goes after the baby is born. However, it increases the chances of the mother developing type 2 diabetes later in life and the child being obese while growing up.
Diabetes care treatment is necessary to enhance the treatment procedure of blood glucose monitoring system. Additionally, diabetes treatment helps enhance the quality of the patient’s life, by controlling the ailment. Diabetes drugs are medicines used for the treatment of type one and type two by reducing the blood glucose level in the body.
Blood glucose is managed by drugs such as Januvia and Byetta, monitoring diet, weight loss, and tracking fitness. Substantial improvements in the blood glucose monitoring systems to provide the critical insulin therapy with the help of insulin pumps and make them reduce painful, more accurate, and easy to use. Several types of drugs involved in the diabetes treatment, which are consumed either orally route or intravenous or subcutaneous routes.
The COVID-19 pandemic moderately impacted on the market. The pace of the market’s growth decreased, due to delays in the treatment of diabetes, as many hospitals were converted into COVID-19 centers. However, to avoid unnecessary visits to hospitals, the demand for diabetes treatment and care increased among patients, which fueled the market to a certain limit.
Diabetes Treatment Market Dynamics
Urbanization, sedentary lifestyles, and obesity around the global are increasing incidences of diabetes. A large number of people lead a fast-paced and a stressful lifestyle, which increases the consumption of unhealthy food habits and alcohol. However, improving standard of living and rising awareness among people about the need for timely treatment are boosting the adoption of diabetes treatments, thereby driving the market.
Growing number of awareness programs by private companies and government organizations is raising awareness about type one and type two diabetes and their treatment, which in turn is projected to propel the market in the coming years. They are also reducing the price of treatments and drugs for diabetes treatment, thus propelling the market.
A large number of people believe in alternative medication and treatment thus, they are increasingly adopting combinational drug treatments. This, in turn, is likely to hinder the market during the forecast period.
Lack of awareness about the novel treatments and their high cost are likely to discourage the elderly and the economically backward population from adopting these treatments, thereby hampering the market.
Invests in the development of treatments, technology, and commercialization of diabetes treatments by companies are likely to create opportunities in the market during the forecast period.
Scope of the Diabetes Treatment Market Report
The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Diabetes Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Product (Injectable Diabetes Drugs, Oral Drugs, Insulin Therapies, Insulin Pumps, Insulin Injection Devices, and Blood Glucose Monitoring Systems), Type (Insulin, Oral Hypoglycemic Drugs, Non-Insulin Injectable Drugs, and Others), End-user (Hospital, Personal Use, and Clinic)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
Key Players Covered in the Report
Abbott Laboratories.; Amylin Pharmaceuticals Inc.; Bayer Healthcare AG; Home Diagnostics Inc.; Johnson & Johnson; Medtronic Inc.; Merck & Company Inc.; Novo Nordisk AS; and Teva Pharmaceuticals Pvt Ltd.
Market Segment Insights
On the basis of product, the market is categorized as injectable diabetes drugs, oral drugs, insulin therapies, insulin pumps, insulin injection devices, and blood glucose monitoring systems. The oral drug segment is projected to account for a considerable share of the market during the forecast period. Moreover, oral drugs consumption is preferred by most of the diabetic patients, as its administration is less painful than injections.
In terms of type, the diabetes treatment market is divided into insulin, oral hypoglycemic drugs, non-insulin injectable drugs, and others. The insulin segment is expected to constitute a significant share of the market during the forecast period. Moreover, increasing incidences of type 1 diabetes and rising number of type 2 diabetes patients relying on insulin are estimated to fuel the segment.
Around 10% of the total diabetes population rely on insulin to manage their high insulin levels. Growing awareness about the benefits of insulin among diabetes patients in emerging economies is driving the insulin segment. Additionally, rapid development in insulin delivery systems, drug and analog development by key companies and growing geriatric population are projected to fuel the segment. According to the International Diabetes Federation states, patients spent USD 760 Billion in 2019, and a large amount of it was spent by Type-1 diabetes patients on insulin drugs.
Based on end-use, the market is classified as hospital, personal use, and clinic. The hospital segment is expected to account for a large share of the market during the forecast period. A large number of patients prefer hospitals for initial diagnostic and treatment of diabetes as pharmacies, medical specialties, and diagnostic centers are easily available under one roof.
In terms of region, the global diabetes treatment market is fragmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to hold a considerable share of the market during the forecast period due to growing investments by various organizations in R&D activities. Additionally, increasing prevalence of diabetes in this region is expected to drive the market in the region. Growing awareness among consumers regarding the novel anti-diabetic drugs, new launch of anti-diabetic drugs, and presence of favorable reimbursement policies are expected to boost the market in the region.
The global diabetes treatment market has been segmented on the basis of
- Injectable Diabetes Drugs
- Oral Drugs
- Insulin Therapies
- Insulin Pumps
- Insulin Injection Devices
- Blood Glucose Monitoring Systems
- Oral Hypoglycemic Drugs
- Non-Insulin Injectable Drugs
- Personal Use
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
Major players in the global diabetes treatment market include Abbott Laboratories.; Amylin Pharmaceuticals Inc.; Bayer Healthcare AG; Home Diagnostics Inc.; Johnson & Johnson; Medtronic Inc.; Merck & Company Inc.; Novo Nordisk AS; and Teva Pharmaceuticals Pvt Ltd. These players engage in R&D investment, product development and launches, partnerships, collaborations, divestitures, geographical penetration, and mergers & acquisitions to increase their global presence and gain an edge over their competitors.
These players are focusing on the development of medication to treat stroke, kidney disease, heart disease, and obesity. They are engaged in research to develop treatment for type one and type two diabetes. A large number of emerging diabetes drugs are awaiting trial and patients are under clinical observation. These drugs are expected to enter the market during the forecast period.
In May 2022, the US Food and Drug Administration (FDA) approved the US-based pharmaceutical company, Eli Lilly’s, Mounjaro (tirzepatide) injection. It is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) used to control blood sugar in adults with type 2 diabetes.